Eosinophilic granulomatosis with polyangiitis
Not recruitingStudy on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis
Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis
- Disease:Eosinophilic granulomatosis with polyangiitis
- Substances:DepemokimabMepolizumab
Austria- Participants:18–64 years · 65+ years
- Substances:Depemokimab







